- Viatris, headquartered in Canonsburg, Pennsylvania, is a global healthcare company that provides access to medicines, including generics and specialty pharmaceuticals, with total revenues of $14.3 billion in 2025.
- In 2025, Viatris completed an enterprise-wide strategic review, anticipating regulatory decisions for six product candidates in 2026 and projecting $650 million in cost savings with $250 million reinvested over three years.
- The company is focused on growing its portfolio of higher-margin generics and value-added medicines, with upcoming product launches including fast-acting Meloxicam and Effexor® for GAD in Japan.
- Viatris targets healthcare providers and payers as ideal buyers, addressing the need for affordable and accessible medications, making it a key player in the evolving pharmaceutical landscape.
Viatris operates with a diverse departmental structure comprising 19 distinct areas. The largest department is Operations, with a headcount of 347, followed closely by Information Technology at 310 and Sales at 300. This distribution reflects a strong emphasis on operational efficiency and technological support, essential in the pharmaceutical sector. The presence of specialized departments such as Legal and Finance, with 129 and 128 employees respectively, indicates a balanced approach to compliance and financial management.
Viatris has a broad geographic footprint with 215 locations, highlighting a significant distribution of its workforce. The headquarters in Canonsburg, PA, employs 278 individuals, making it the largest site, while Morgantown, WV, and New York, NY, contribute 67 and 64 employees, respectively. The large category of 'Other' locations, accounting for 2,244 employees, suggests a decentralized workforce that supports a variety of operational needs across multiple regions. This distribution underscores the company's ability to maintain a flexible and responsive operational model.
